Contemporary Accounts in Drug Discovery and Development

Xianhai Huang, Robert G. Aslanian, Wayne H. Tang, Xianhai Huang, Robert G. Aslanian, Wayne H. Tang

• Publisher: Wiley
• Year: 2022
• Print ISBN: 9781119627715
• eBook ISBN: 9781119627852
• Edition: 1
• Topic: Medicine
• Subtopic: Pharmacology

CONTEMPORARY ACCOUNTS IN DRUG DISCOVERY AND DEVELOPMENT

A useful guide for medicinal chemists and pharmaceutical scientists

Drug discovery is a lengthy and complex process that typically involves identifying an unmet medical need, determining a biological target, chemical library screening to identify a lead, chemical optimization, preclinical studies and clinical trials. This process often takes many years to complete, and relies on practitioners' knowledge of chemistry and biology, but also—and perhaps more importantly—on experience. Improving the success rate in discovery and development through a thorough knowledge of drug discovery principles and advances in technology is critical for advancement in the field.

Contemporary Accounts in Drug Discovery and Development provides drug discovery scientists with the knowledge they need to quickly gain mastery of the drug discovery process. A thorough accounting is given for each drug covered within the book, as the authors provide pharmacology, drug metabolism, biology, drug development, and clinical studies for every case, with modern drug discovery principles and technologies incorporated throughout.

Contemporary Accounts in Drug Discovery and Development readers will also find

• Case histories used as an engaging way of learning about the drug discovery/development process
• Detailed biological rational and background information, drug design principles, SAR development, ADMET considerations, and clinical studies
• The full history of individual marketed small molecule drugs
• Coverage of drug candidates that have passed Phase I clinical trials with different modalities, such as antibody drug conjugates (ADC), proteolysis-targeting chimera (PROTAC), and peptide drugs
• The application of new technologies in drug discovery such as DNA-encoded libraries (DEL), positron emission tomography (PET), and physics-based computational modeling employing free energy perturbation (FEP)

Contemporary Accounts in Drug Discovery and Development is a helpful tool for medicinal chemists, organic chemists, pharmacologists, and other scientists in drug research and process development. It may be considered essential reading for graduate courses in drug discovery, medicinal chemistry, drug synthesis, pharmaceutical science, and pharmacology. It is also a useful resource for pharmaceutical industry labs, as well as for libraries.

Table of contents

• Cover
• Title Page
• Copyright Page
• Contents
• Preface
• List of Contributors
• Chapter 1 Current Drug Discovery: Great Challenges and Great Opportunity (an Introduction to Contemporary Accounts in Drug Discovery and Development)
• Chapter 2 Advanced Computational Modeling Accelerating Small-Molecule Drug Discovery: A Growing Track Record of Success
• Chapter 3 Discovery and Development of the Soluble Guanylate Cyclase Stimulator Vericiguat for the Treatment of Chronic Heart Failure
• Chapter 4 Finding Cures for Alzheimer’s Disease: From -Secretase Inhibitors to -Secretase Modulators and -Secretase Inhibitors
• Chapter 5 Discovery of Novel Antiviral Agents Enabled by Structural Biology, Compact Modules and Phenotypic Screening
• Chapter 6 Discovery of Subtype Selective Agonists of the Group II Metabotropic Glutamate Receptors
• Chapter 7 Discovery of Taselisib (GDC-0032): An Inhibitor of PI3K with Selectivity over PI3K
• Chapter 8 Drug Discovery with DNA-Encoded Library Technology: Inhibitor of Soluble Epoxide Hydrolase to Clinical Candidate
• Chapter 9 Discovery of HTL26119: Family B GPCR Structure-Based Drug Design Is Now a Reality
• Chapter 10 Discovery and Potential Application of [11C]MK-6884: A Positron Emission Tomography Imaging Agent for the Study of M4 Muscarinic Receptor Positive Allosteric Modulators in Neurodegenerative Diseases
• Chapter 11 Targeted Protein Degradation by Proteolysis Targeting Chimeras: A Revolution in Small Molecule Drug Discovery
• Chapter 12 Entrepreneurial Drug Hunter: Macrocyclic Peptide Modalities
• Chapter 13 Application of Pyrrolobenzodiazepines in Antibody Drug Conjugates
• Chapter 14 Combination Therapy Case Studies in Anticancer and Anti-Infectious Disease Drug Discovery and Development
• Chapter 15 Accelerating Drug Discovery and Development: Translational Medicine in Combating the COVID-19 Pandemic
• Appendix A Monoclonal Antibody Drug Discovery and Development Paradigm
• Appendix B Glossary
• Appendix C Abbreviations
• Index
• EULA